Sphingosine-1-Receptor Modulators Drugs Market

Sphingosine-1-phosphate receptor 1 (S1P receptor 1 or S1P1), also known as endothelial differentiation gene 1 (EDG1) is a protein that in humans is encoded by the S1PR1 gene. S1PR1 is a G-protein-coupled receptor which binds the bioactive signaling molecule sphingosine 1-phosphate (S1P). S1PR1 belongs to a sphingosine-1-phosphate receptor subfamily comprising five members (S1PR1-5). S1PR1 was originally identified as an abundant transcript in endothelial cells and it has an important role in regulating endothelial cell cytoskeletal structure, migration, capillary-like network formation and vascular maturation. In addition, S1PR1 signaling is important in the regulation of lymphocyte maturation, migration and trafficking.

Sphingosine-1-Receptor Modulators Drugs Market contains market size and forecasts of Sphingosine-1-Receptor Modulators Drugs in global, including the following market information:

Global Sphingosine-1-Receptor Modulators Drugs Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global Sphingosine-1-Receptor Modulators Drugs Market Sales, 2017-2022, 2023-2028, (K Units)

Global top five Sphingosine-1-Receptor Modulators Drugs companies in 2021 (%)

The global Sphingosine-1-Receptor Modulators Drugs market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Fingolimod Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Sphingosine-1-Receptor Modulators Drugs include Novartis, Bristol-Myers Squibb, Johnson & Johnson, Arena Pharmaceuticals, Idorsia, Sun Pharma, Biocon and HEC Pharm Co. Limited, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Sphingosine-1-Receptor Modulators Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Sphingosine-1-Receptor Modulators Drugs Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Sphingosine-1-Receptor Modulators Drugs Market Segment Percentages, by Type, 2021 (%)

Fingolimod

Siponimod

Ozanimod

Other

Global Sphingosine-1-Receptor Modulators Drugs Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Sphingosine-1-Receptor Modulators Drugs Market Segment Percentages, by Application, 2021 (%)

Hospital

Clinic

Other

Global Sphingosine-1-Receptor Modulators Drugs Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Sphingosine-1-Receptor Modulators Drugs Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Sphingosine-1-Receptor Modulators Drugs revenues in global market, 2017-2022 (Estimated), ($ millions)

Key companies Sphingosine-1-Receptor Modulators Drugs revenues share in global market, 2021 (%)

Key companies Sphingosine-1-Receptor Modulators Drugs sales in global market, 2017-2022 (Estimated), (K Units)

Key companies Sphingosine-1-Receptor Modulators Drugs sales share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Novartis

Bristol-Myers Squibb

Johnson & Johnson

Arena Pharmaceuticals

Idorsia

Sun Pharma

Biocon

HEC Pharm Co. Limited